Inactive Instrument

Highlights CEL-SCI Corporation Nyse

Equities

US1508374097

End-of-day quote Nyse Other stock markets
- ^USD	-

May. 15	CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI
May. 08	Cel-Sci Gets US FDA Clearance to Proceed With Confirmatory Study for Cancer Drug Multikine	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	May. 15	CI
CEL-SCI Corporation Announces Significantly Positive Outcome from its Recent Meeting with U.S. Food and Drug Administration Regarding Path to Approval for its First-Line Investigational Cancer Immunotherapy Multikine	May. 08	CI
CEL-SCI Corporation Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer	May. 08	CI
CEL-SCI Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 14	CI
CEL-SCI Corporation Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug	Feb. 06	CI
Cel-Sci Receives Pediatric Requirements Waiver for Multikine From European Medicines Agency	Jan. 31	MT
North American Morning Briefing : S&P 500 Futures Just Shy of Record High	Dec. 28	DJ
CEL-SCI Corporation Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 21	CI
CEL-Sci Corporation Releases Video Detailing Recent Phase 3 Findings & Its Plans to Seek Immediate Regulatory Approvals	23-10-24	CI
CEL-SCI Presents the Data for the First Time at the European Society for Medical Oncology Congress in Spain	23-10-23	CI
CEL-SCI Corporation Readies Its Multikine Manufacturing Facility for Commercial Scale Production	23-10-19	CI
Cel-Sci Files Request With UK Regulator for Approval Pathway of Multikine to Treat Head, Neck Cancer	23-10-05	MT
Cel-Sci Files Request with the Uk's Mhra Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer	23-10-05	CI
Cel-Sci Submits Scientific Advice Filing to European Medicines Agency for Multikine in the Treatment of Head & Neck Cancer	23-09-26	CI
CEL-SCI Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-10	CI
CEL-SCI Corporation Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikineâ€™s Increased Efficacy and Points to Potential for Combination with Checkpoint Inhibitors for Head & Neck Cancer	23-07-12	CI
CEL-SCI Corporation to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer--New Patent to Be Filed	23-06-22	CI
CEL-SCI Corporation Announces Latest Results from Its Pivotal Phase 3 Study of Multikine	23-05-15	CI
CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-12	CI
CEL-SCI Corporation Reports New Data from Its Pivotal Phase 3 Study	23-03-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights CEL-SCI Corporation Nyse

Equities

US1508374097

Highlights

Filters